Contrast agents are diagnostic tools that often complement magnetic resonance imaging. At ultra-high field strengths ($7 T), magnetic resonance imaging is capable of generating desirable high signal-tonoise ratios, but clinically available contrast agents are less effective at ultra-high field strengths relative to lower fields. This gap in effectiveness demands the development of contrast agents for ultra-high field strengths. In this minireview, we summarize contrast agents reported during the last three years that focused on ultra-high field strengths.
Introduction
Magnetic resonance imaging (MRI) is a non-invasive technique that can map the relaxation rates of water protons in a magnetic eld to generate images. Common clinical magnetic eld strengths are 1.5 and 3 T, but the number of higher eld strength systems increases each year. Over forty clinical and preclinical 7 T MRI scanners are available in the United States, and many higher eld strength scanners ($7 T) are used in preclinical research.
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Magnetic elds at or above 7 T are classied as ultra-high eld strengths, and the use of 7 T magnets for clinical MRI has been reported. [5] [6] [7] [8] There is a strong urge to use ultra-high eld MRI scanners because of the advantages that can be gained with ultra-high eld strengths relative to lower eld strengths, including high signal-to-noise ratios, high spatial resolution, short acquisition times, and the ability to use low sensitivity nuclei other than 1 H (including 19 F, 13 C, 23 Na, and 31 P).
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These advantages are demonstrated by the increased amount of information that can be gained from MR images at ultra-high eld strengths compared to lower eld strengths (Fig. 1) .
Obtaining high quality MR images (high contrast-to-noise ratios) is critical in diagnosing diseases, but increases in magnetic eld strength alone are not always sufficient to obtain images with high contrast-to-noise ratios. High contrast-tonoise ratios oen can be achieved using paramagnetic metal complexes called contrast agents. 9 For example, complexes 1-6 shown in Fig. 2 are clinically approved contrast agents that are used to improve contrast-to-noise ratios in MR images in approximately half of all clinical scans. [9] [10] [11] [12] Contrast agents inuence both longitudinal (1/T 1 ) and transverse (1/T 2 ) relaxation rates, and clinically approved contrast agents can be categorized into two types of agents: those with T 1 /T 2 ratios close to one (T 1 -shortening or positive agents) and those with T 1 /T 2 ratios $6 (T 2 -shortening or negative agents). 12, 13 Both types of contrast agents usually contain paramagnetic metal ions that increase the relaxation rates (1/T 1 and 1/T 2 ) of the protons of the surrounding molecules, but current clinical contrast agents are less effective at ultra-high magnetic elds than at lower elds (Table 1) . [14] [15] [16] Note: care should be taken to only compare relaxivity values reported at the same temperature and in the same solvent.
Because of the decrease in relaxivity with increasing eld strength, a great deal of research has focused on modifying Gd III -based agents to increase relaxivity at ultra-high eld strengths. Additionally, other types of contrast agents have been studied to meet the need of efficient contrast agents at ultrahigh elds. Much of this work has been reviewed, 13, [17] [18] [19] [20] [21] [22] [23] [24] [25] and this review is intended to describe both Gd III -based and non-Gd IIIbased strategies to inuence contrast in ultra-high eld MRI from the last three years with a focus on discrete molecules. For reviews focused on nanoparticles, we suggest a few other reviews. (1) Optimization of Gd
III -based agents
Molecular parameters that inuence the relaxivity of T 1 -shortening agents include the number of coordinated water molecules and the electronic relaxation, water-exchange, and rotational correlation rates. This review does not go into detail regarding these properties because they have been described elsewhere; [34] [35] [36] [37] however, at eld strengths higher than 1.5 T, the electronic relaxation rates do not contribute signicantly to relaxivity, 37 but water-exchange and rotational correlation rates need to be optimized as a function of eld strength to achieve fast longitudinal relaxation rates of the protons of the surrounding molecules. 36 Another parameter that inuences relaxivity is the number of coordinated water molecules. Increasing this number usually increases relaxation rates but oen leads to complexes with lowered kinetic stabilities.
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However, incorporation of multiple complexes into one molecule is a way to inuence the rotational correlation rate and the number of coordinated water molecules without necessarily sacricing kinetic stability.
Apart from the number of coordinated water molecules, the relaxivities of clinically used T 1 -shortening contrast agents (1-6, Fig. 2 ) are limited by fast rotational correlation rates (waterexchange rates do not play a large role in relaxivity at ultra-high elds for Gd III -based T 1 -shortening agents until rotational correlation rates have been optimized); 13 therefore, optimizing rotational correlation rates is essential to achieve high relaxivity. To slow rotational correlation rates, conjugation to relatively large molecules such as proteins has been studied (the use of macromolecules also inuences biodistribution and half-life in vivo). [39] [40] [41] Although macromolecule-conjugation is effective at lower eld strengths (#3 T), this strategy causes too much slowing of the rotational correlation rates and negatively impacts relaxivity at ultra-high eld strengths. To achieve the best relaxivity above 3 T, it is necessary to bring the rotational correlation rate to an intermediate range (2.5 Â 10 8 to 2 Â 10 9 s À1 ). 36, 38 Rotational correlation rate is inuenced by the molecular weight and exibility of a complex; therefore, by slightly increasing the steric bulk or by linking multiple Gd III -containing complexes together, the rotational correlation rate can be targeted to the desired region for a specic eld strength.
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Meade and co-workers reported the conjugation of multiple Gd III -containing complexes via 5-(2,4,6-triethenylphenoxy)pentanoic acid to produce trimeric complex 7 with rigid triazole linkers to bring the rotational correlation rate to an intermediate range (Fig. 3) . 42 Complex 7 displays a 170% higher per Gd relaxivity (Table 2 ) at ultra-high elds compared to unconjugated complex 8 due to the decrease in rotational correlation rate from 2 Â 10 10 to 1.7 Â 10 9 s À1 .
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Another example of optimizing rotational correlation rate was reported by Yang and co-workers. 43 They metalated the apo proteins ProCA1 and polyethylene glycol (PEG)-conjugated ProCA1 with Gd III (Fig. 4) . The relaxivities of PEGylated Gd III -containing ProCA1 proteins are higher at ultra-high eld strengths than non-PEGylated Gd III -containing ProCA1 ( Table 2 ). Wang and co-workers reported myelin-specic Gd III -based contrast agents 9 and 10 that have higher relaxivities than 1 (3.9 mM À1 s À1 at 9.4 T and 25 C) or 2 (4.1 mM À1 s À1 at 9.4 T and 25 C) at ultra-high eld strengths due to the increase in molecular weight resulting from conjugation with stilbene or coumarin derivatives (Table 2) . 44, 45 Chuang, Yang, and coworkers reported complex 11 as a potential tumour-targeting ) per ion of T 1 -shortening contrast agents at 37 C (unless otherwise noted) and 1.4, 3, 4.7, 7, 9.4, and 11. contrast agent that displays higher relaxivities than clinically approved contrast agents 1 or 2 at 9.4 T ( Table 2) . 46 Hagberg and co-workers reported a calcium ion sensitive contrast agent 12 that increased the relaxivity from 2.9 to 6.5 mM À1 s À1 at 37 C and at 7 T as a function of the concentration of Ca 2+ . 51 Caravan and co-workers reported Gd III -DOTAla-based complexes 13-18
that have rotational rates (1.7 Â 10 9 to 6.7 Â 10 9 s À1 ) and waterexchange rates that are near optimal at ultra-high eld strengths. 47 Complexes 13-18 have higher relaxivities compared to clinically approved contrast agents 4 (3.0 mM À1 s À1 at 37 C) and 5 (4.8 mM À1 s À1 at 37 C) at 9.4 T ( Table 1) . 47 Bates and coworkers synthesized complexes 19 and 20 that display higher per Gd relaxivities compared to clinically used contrast agents 1 and 2 at 9.4 T. 48 Complex 19 is seven coordinate (Gd  III usually has a coordination number of nine); therefore, two remaining coordination sites can be occupied by water molecules to produce a water-coordination number of two. A higher watercoordination number and larger molecular weight caused complex 19 to have a higher relaxivity than clinically approved contrast agents. However, adjacent water-coordination sites are prone to coordination by bidentate anions like carbonates and phosphates leading to low relaxivities in biologically relevant media. 52 Complex 20, relative to 19, contains an octadentate ligand leaving only one site for water, but due to the higher molecular weight, complex 20 displays a slower rotational correlation rate leading to higher relaxivity than clinical contrast agents at ultra-high elds. Angelovski and co-workers reported a series of Gd III -based complexes (21-24) that display higher relaxivities than clinically approved contrast agents 1 and 2 at 7 T and 25 C (Table 2) .
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The examples in this section demonstrate the inuence of rotational correlation rate and the number of coordinated water molecules on relaxivity at ultra-high eld strengths. Although these examples show increases in relaxivity at ultra-high elds compared to clinically approved T 1 -shortening contrast agents, the relaxivities per metal ion for complexes 7-24 are only slightly larger than the relaxivities of clinically approved T 1 -shortening contrast agents at ultra-high eld strengths and 37 C. This small increase has generated interest in alternatives to Gd III -based contrast agents, and these agents are described in the remaining sections of this review. 
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Allen and co-workers reported a series of Eu II -containing cryptates 25-27 ( Fig. 5 ) that are more efficient contrast agents than 2 (3.7 mM À1 s À1 at 7 T and 19 C) at ultra-high eld strengths (Table 2) . 50 The higher relaxivities of Eu II -containing cryptates relative to 2 at ultra-high elds are due to the ability to accommodate two water molecules in the inner sphere, the increase in water-exchange rates, and changes in rotational correlation rates compared to 2. 50, 56 The differences in relaxivities among different cryptates arise mainly from the changes in the rotational correlation rates that are proportional to molecular weight differences. F-MRI is increased with the use of ultrahigh eld strengths because signal intensity is proportional to eld strength. This increase in signal intensity results in lower amounts of uorinated agents being needed to obtain MR images (usually 19 F-MRI requires concentrations of 19 F to be in the millimolar range for imaging). 63 Because of the low sensitivity for detection of 19 F by MRI, two strategies have been reported to increase the sensitivity of 19 F-MRI. The rst strategy is to incorporate as many 19 F atoms into the structure as possible, and the other strategy is to incorporate a lanthanide ion to inuence the relaxation rate of nearby 19 F nuclei.
63
Increases in relaxation rates also allow for faster acquisition rates in imaging.
64
A series of 19 F-labeled lanthanide-based contrast agents (28-32, Fig. 6 ) were reported by Blamire and co-workers. 63 They used phosphonate-based 1,4,7,10-tetraazacyclododecane-1,4,7-triacetate (DO3A)-type ligands that were metalated with different lanthanide ions. Selection of the lanthanide ion and the imaging parameters were found to be key factors for using these agents for ultra-high eld applications. Blamire and co-workers also reported that Dy III -containing complex 29 provided the highest relaxation rates of the group at 4.7, 7.0, and 9.4 T ( Table  3 ). Due to the high contrast gained from incorporation of Dy phantom images compared to the typical sensitivity of 19 F-MRI that is usually in the millimolar range. 63 Incorporation of lanthanide ions have been reported by Parker and co-workers with a phosphonate-based Dy III -DO3A conjugated to chitosan (a linear polysaccharide) to result in complex 33 ( Fig. 6 ) that shows comparable longitudinal relaxation rates to complex 29 at 4.7 and 9.4 T ( Table 3) . 65 Conjugation of chitosan improved the retention time of complex 33 in vivo leading to lower amounts of the contrast agent being needed for imaging.
Faber and co-workers reported complexes 34-37.
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Complexes 34 and 35 displayed higher relaxation rates (Table 3) and signal-to-noise ratios than complexes 36 and 37 at 9.4 T, leading to higher sensitivities. Kikuchi and co-workers reported contrast agents 38 and 39 that show decreased relaxation rates in the presence of enzymes. F, another type of MRI experiment is chemical exchange saturation transfer (CEST) that uses proton transfer between two chemically distinct proton pools to produce images. In CEST, one pool is saturated by a radio frequency pulse, and chemical exchange of saturated protons with the bulk water decreases the signal intensity of the bulk water. The difference in the signal intensities before and aer exchange can be mapped to produce images. 69 This imaging modality can be used to monitor changes in pH, temperature, and analyte concentration (anions and metal ions). 70, 71 At ultra-high eld strengths, high signal intensities for CEST can be achieved because, as with 19 F, signal intensity depends on the eld strength. 24, 69 Also, the separation between signals from CEST agents and bulk water increases with eld strength. When the signal from a CEST agent is close (<5 ppm) to the bulk water signal, saturation pulses can excite protons in both pools decreasing the signal intensity (CEST effect) before the proton exchange can take place. Interference with saturation frequency can be reduced by making the exchangeable pool appear farther from the bulk water signal (>5 ppm). Large frequency differences between the two pools also allow the use of relatively fast proton-exchange rates (for CEST agents, protonexchange rates above 10 3 s À1 are considered fast) instead of the typically desired slow exchange rates ($2 Â 10 3 s
À1
). 72, 73 This range of proton-exchange rates allows the use of CEST agents, including lanthanide-based paramagnetic CEST (PARACEST) agents that usually have intermediate to fast proton-exchange rates. PARACEST agents are mainly paramagnetic metal complexes that contain exchangeable protons. Because of the paramagnetic center, the exchangeable proton signal is shied farther from the bulk water signal than in the case of CEST agents. This shi from the bulk water signal increases the sensitivity of the PARACEST agent. This shiing is especially important in vivo where there are many endogenous exchangeable protons. The following section describes the recent examples of CEST and PARACEST agents.
A series of thymidine-based (40-43, Fig. 7 ) CEST agents have been reported by Gilad and co-workers at 3 and 11.7 T. 74 For compounds 40 and 41, distinguishable peaks ($5 ppm from the bulk water signal) for amide protons were not observed at 3 T due to fast proton-exchange rates ($3.7 Â 10 3 s À1 ), but at 11.7 T both 40 and 41 showed peaks distinct from the bulk water peaks. Compounds 42 and 43 showed signals for amide protons 5 ppm from the bulk water signal at both eld strengths, but the peaks at 11.7 T were prominent because of the slow protonexchange rate (#1.7 Â 10 3 s À1 ). 74 CEST agents that show greater shis from bulk water than thymidine-based agents have been reported by Pomper, McMahon, and co-workers. 75 These agents contain salicylic acid or its analogues (44-50, Fig. 7) . Compounds 44-50 displayed shis of 8.7-10.8 ppm from bulk water at 11.7 T at pH 7 and 37 C. Compound 51 (Fig. 7) has been reported by Bulte, McMahon, and co-workers, and they 
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showed that CEST activity detected with 19 F-NMR can be used to detect Ca 2+ selectively in the presence of Mg 2+ and Zn 2+ (Ca 2+ results in slow exchange rates compared to Mg 2+ and Zn 2+ ).
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The Ca 2+ -containing complex shows 6.2 ppm shi from the free ligand. The uorinated free ligands and metal-bound ligands were used as the exchangeable nuclei and 19 F-MRI was used to observe CEST activity.
A series of Ln III -and transition metal-based PARACEST complexes (52-67, Fig. 7 ) were reported by Morrow and coworkers. 71, [77] [78] [79] [80] [81] [82] [83] Complex 52 displayed changes in CEST effect in response to the presence or absence of the biologically important anions lactate, citrate, and phosphate at 11.7 T and pH 6.5.
71 Complex 52 showed a chemical shi of 6 ppm from the bulk water signal in the CEST spectrum due to exchangeable alcohol protons. The addition of lactate and acetate shied the peak to 7 ppm, and in the presence of citrate, the peak shied to 8 ppm. Complexes 53 and 54 displayed changes in CEST effect in response to the interaction of phosphate diesters at neutral pH values.
77 Complex 53 showed a CEST signal around 5 ppm with respect to the bulk water when one equivalent of diethyl phosphate was added. Similarly, complex 54 displayed a CEST signal around 20 ppm with respect to bulk water when diethyl phosphate was added. Fe II -containing PARACEST agents 55 and 56 displayed changes in CEST effect with respect to pH.
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Complex 55 showed a CEST signal at 54 ppm, and the intensity of the peak decreased with increasing pH from 6.4 to 7.3 at 11.7 T and at 37 C. The signal intensity of complex 56 at 50 ppm from the bulk water increases in intensity with increasing pH from 6.8 to 7.6. 81 Complexes 58 and 61 showed 69 and 6 ppm shis, respectively, from bulk water at 9.4 T. 78 The smaller shi observed with complex 61 compared to 58 was attributed to the slower proton-exchange rates of anilines compared to amides.
Complexes 59, 62, and 64 are Ni II -containing PARACEST agents. The most intense CEST effect of the three was observed for complex 64 at 76 ppm from bulk water at 11.7 T.
79
Complexes 59 and 62 showed CEST effects at 76 and 72 ppm, respectively, from bulk water at 11.7 T, but the effects were 2-4-fold lower than that of complex 64. 79 A series of Co II -containing complexes 57, 60, 63, 65, and 67 have also been reported.
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The redox active complex 67 was studied at 11.7 T as a potential probe to map in vivo oxygen levels. 80 Complex 67 with a CEST effect at 135 ppm from bulk water becomes CEST silent in the presence of oxygen.
80 Complexes 57, 60, 63 , and 65 displayed pH sensitive CEST effects in the pH range 6.5-7.5.
82 CEST signals for complexes 57 and 60 were at 45 and 32 ppm, respectively, and the signals for complex 65 were at À19 and 59 ppm.
82
Complex 63 displayed four CEST signals (112, 95, 54, and 45 ppm), and all shis were measured at 11.7 T and 37 C.
Complexes 64-66 were reported for their pH sensitive CEST effects between pH 6.5 and 7.7. 83 Complexes 64-66 displayed CEST signals at 72, 59, and 92 ppm, respectively, with CEST effects ranging from 25 to 39%.
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Kovacs and co-workers reported a Eu III -containing PARAC-EST agent (68, Fig. 7 ) that can be activated by a redox reaction.
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The complex contained nitroxide free radicals that slow the longitudinal relaxation rates of amide protons, but aer oxidation in the presence of ascorbic acid, nitroxide radicals convert to nitroxide, resulting in an increase of the CEST effect to 20% at 9.4 T and 50 ppm from the bulk water. 84 Coman, Hyder, and co-workers reported a temperature-sensitive Eu IIIbased PARACEST agent (69, Fig. 7 ) that enhanced the intensity of the CEST effect between 25 and 40 C and decreased the intensity above 40 C at 11.7 T due to increased water-exchange rate at high temperature. 85 Angelovski, Tóth, and co-workers reported calcium-ion-responsive PARACEST agents 70 and 71 that displayed a 60% CEST effect at 41 ppm and a 35% effect at À11 ppm, respectively, due to the exchange of amide protons in the absence of calcium ions (11.7 T, 37 C, and pH 7.4). 86 The addition of calcium ions decreased the signal intensities due to the slowing of amide proton exchange. Durand, Tóth, and coworkers reported pH responsive PARACEST agents 72 and 73 that displayed CEST signals at about À25 ppm from bulk water at 11.7 T and 37 C. 87 For complex 73, a decrease in CEST effect from 65 to 15% was observed upon increasing the pH from 6.3 to 9.
87 Kotek and co-workers also reported pH responsive PAR-ACEST agents. [91] [92] [93] [94] Complex 80 reacts with esterases to produce hydrocoumarins and amine-functionalized metal complexes that in turn produce a CEST signal at 12 ppm (14 T, 37 C, and pH 7.4). 91 Complex 81 reacts with the enzyme transglutaminase to form a covalent bond between the metal complex and albumin, decreasing the CEST effect caused by albumin at 4.6 ppm and leading to the appearance of a new signal at À9.2 ppm (14 T, 37 C, and pH 7.4). 92 Complex 82, on the other hand, becomes CEST silent aer reacting with the enzyme urokinase (before the enzyme reaction, the metal complex displays a signal at À54.1 ppm at 7.05 T and 37 C). 93 Complex 83 displayed CEST signals at À9.8 and 9.75 ppm, and the ratio between the intensities of these signals changes linearly with respect to changes in pH between 6.0 and 7.6 (14 T and 38.3 C).
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Hudson and co-workers synthesized a series of PARACEST agents 84-87 to study the CEST effect. 95, 96 The CEST effects of complexes 84-86 were greater than 18%, whereas the analogous Tm III -and Dy III -containing complexes produced CEST effects less than 18%. 95 Complex 87 also has been studied for its pH responsive CEST effect. 96 This complex produced a six-fold increase in CEST effect upon changing pH from 6.5 to 7.0 (9.4 T and 37 C).
96
As demonstrated by the examples in this section, CEST agents can be effectively used at ultra-high eld strengths to monitor biologically relevant environmental changes. Although CEST agents are versatile in terms of monitoring changes in environments, they suffer from low sensitivity which is a prime area for research.
Summary and conclusions
Ultra-high eld strength MRI is capable of generating images with high signal-to-noise ratios potentially making detection of pathologies more accurate. Contrast agents have been used to achieve high contrast between pathologies and the surrounding environment, but clinically approved contrast agents are less efficient at ultra-high eld strengths relative to low eld strengths. Optimization of molecular parameters to increase the efficiency of Gd III -based contrast agents at ultra-high elds and other non-Gd III -based strategies have been reported and are being investigated by a number of research groups. There is opportunity for different types of contrast agents to be used in ultra-high eld applications, but further research is needed for all of these strategies. A possible future for ultra-high eld contrast agents will likely consist of a combination of these strategies.
